Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis
Sponsor: Astellas Pharma Europe B.V.
Listed as NCT02273726, this PHASE3 trial focuses on CKD Anemia in Stable Dialysis Patients and remains completed. Sponsored by Astellas Pharma Europe B.V., it has been updated 14 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE3
-
May 2019 — Dec 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
May 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Europe B.V.
- AstraZeneca
- Kyntra Bio
For direct contact, visit the study record on ClinicalTrials.gov .